Cargando…

Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease

Pulmonary hypertension (PH) with developmental lung disease is a life-threatening disease and accounts for 10%–12% of pediatric PH patients. Administration of specific pulmonary vasodilators to pediatric PH patients has brought about improvement of their long-term prognosis. Intravenous epoprostenol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukasawa, Yoshie, Yamamoto, Hidenori, Ito, Miharu, Saito, Akiko, Go, Kiyotaka, Morimoto, Yoshihito, Yasuda, Kazushi, Sato, Yoshiaki, Hayakawa, Masahiro, Kato, Taichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020523/ https://www.ncbi.nlm.nih.gov/pubmed/36937960 http://dx.doi.org/10.3389/fped.2023.1116434

Ejemplares similares

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Successful Weaning From Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO) After Initiation of Inhaled Epoprostenol in a Neonate With Refractory Persistent Pulmonary Hypertension of the Newborn (PPHN)
por: Shehzad, Irfan, et al.
Publicado: (2023)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
por: Kitase, Yuma, et al.
Publicado: (2020)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
por: Poonam, Pai B. H., et al.
Publicado: (2022)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

Altered offspring neurodevelopment in an L-NAME-induced preeclampsia rat model
por: Nakamura, Noriyuki, et al.
Publicado: (2023)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Bridging the Gap: Parents’ Knowledge of Childhood Developmental Milestones and the Early Identification of Children With Developmental Delay
por: Alghamdi, Haitham M, et al.
Publicado: (2023)

Temperature Variations around Medication Cassette and Carry Bag in Routine Use of Epoprostenol Administration in Healthy Volunteers
por: Tamura, Yuichi, et al.
Publicado: (2012)

Developmental Origins and Nephron Endowment in Hypertension
por: Gurusinghe, Shari, et al.
Publicado: (2017)

Developmental Mutators and Early Onset Cancer
por: Kentsis, Alex, et al.
Publicado: (2020)

Outcomes in symptomatic preterm infants with postnatal cytomegalovirus infection
por: Takemoto, Koji, et al.
Publicado: (2021)

Erythema and Induration of Bacillus Calmette-Guérin Scar Associated With Multisystem Inflammatory Syndrome in Children in Japan: A Case Report
por: Tsuboya, Naoki, et al.
Publicado: (2022)

Predictors of Developmental Patterns of Obesity in Young Children
por: O'Connor, Thomas G., et al.
Publicado: (2020)

Developmental defects of enamel in children born preterm
por: Halperson, Elinor, et al.
Publicado: (2022)

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
por: Guan, Zheng, et al.
Publicado: (2018)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment
por: Woyke, Simon, et al.
Publicado: (2022)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

BRIGHT Coaching: A Randomized Controlled Trial on the Effectiveness of a Developmental Coach System to Empower Families of Children With Emerging Developmental Delay
por: Majnemer, Annette, et al.
Publicado: (2019)

Developmental Profile and Diagnoses in Children Presenting with Motor Stereotypies
por: Cardona, Francesco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h35cs1kvqd9mabn9uh48j4l0l7